Feasibility Study on Biweekly Paclitaxel Treatment as Maintenance Chemotherapy in Advanced Müllerian Carcinoma

2012 ◽  
Vol 73 (4) ◽  
pp. 272-276
Author(s):  
Yukihisa Minagawa ◽  
Muneaki Shimada ◽  
Hiroaki Itamochi ◽  
Shinya Sato ◽  
Seiya Sato ◽  
...  
Keyword(s):  
Feasibility Study ◽  
Maintenance Chemotherapy ◽  
Müllerian Carcinoma ◽  
Paclitaxel Treatment

Docetaxel for Patients With Paclitaxel-Resistant Müllerian Carcinoma

2000 ◽  
Vol 18 (14) ◽  
pp. 2733-2739 ◽  
Author(s):  
Claire F. Verschraegen ◽  
Tul Sittisomwong ◽  
Andrzej P. Kudelka ◽  
Ernesto de Paula Guedes ◽  
Melissa Steger ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube Cancer ◽  
Peritoneal Cancer ◽  
Free Interval ◽  
Docetaxel Treatment ◽  
Progression Of Disease ◽  
Previously Treated ◽  
Müllerian Carcinoma ◽  
Paclitaxel Treatment

PURPOSE: To determine the efficacy and toxicity of docetaxel in patients with müllerian carcinoma resistant to paclitaxel. PATIENTS AND METHODS: Thirty-two patients with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who failed paclitaxel-based chemotherapy received either 100 or 75 mg/m2 of docetaxel every 3 weeks. Resistance to paclitaxel was defined as either progression of disease during treatment, failure to achieve regression of disease after at least four courses, or rapid recurrence (within 6 months) after completion of therapy. RESULTS: Eighteen patients were treated on a formal protocol and fourteen with the commercially available docetaxel. Thirty were assessable for response. Toxicities were thoroughly evaluated in the 18 patients on protocol. Twenty-seven patients (85%) had epithelial ovarian cancer. The overall response rate was 23% (one complete and six partial responses), with a median survival time of 44 weeks (9.5 months). Nine patients had stable disease and 14 progressive disease. Among 19 patients who progressed during prior paclitaxel treatment, two (11%) responded to docetaxel, compared with five (45%) of 11 patients in other paclitaxel-resistance categories. The responders had a median taxane-free interval (ie, the time between the last paclitaxel and first docetaxel treatment) of 73 weeks, compared with 19 weeks for the nonresponder group. Toxic effects were as expected. CONCLUSION: Docetaxel is an active chemotherapeutic agent in patients with müllerian carcinoma previously treated with paclitaxel-based chemotherapy, especially in the patients who had a long taxane-free interval after a previous short response to paclitaxel.

Hyperfractionated Accelerated Radiotherapy (HART) with maintenance chemotherapy for metastatic (M1–3) Medulloblastoma – A safety/feasibility study

2014 ◽  
Vol 111 (1) ◽  
pp. 41-46 ◽  
Author(s):  
Roger E. Taylor ◽  
Andrew J. Howman ◽  
Keith Wheatley ◽  
Elena E. Brogden ◽  
Bridget Large ◽  
...  
Keyword(s):  
Feasibility Study ◽  
Maintenance Chemotherapy ◽  
Accelerated Radiotherapy

Feasibility Study of the Development, Implementation, and Evaluation of Computer-Based Job and Occupational Data Collection Methods

1998 ◽  
Author(s):  
J. L. Mitchell ◽  
Winston Bennett ◽  
J. J. Weissmuller ◽  
R. L. Gosc ◽  
Patricia Waldroop ◽  
...  
Keyword(s):  
Data Collection ◽  
Feasibility Study ◽  
Data Collection Methods ◽  
Computer Based ◽  
Collection Methods

Getting better my way: Feasibility study of a self-management support tool for people with mood and anxiety disorders.

2019 ◽  
Vol 42 (2) ◽  
pp. 158-168
Author(s):  
Janie Houle ◽  
Stephanie Radziszewski ◽  
Préscilla Labelle ◽  
Simon Coulombe ◽  
Matthew Menear ◽  
...  
Keyword(s):  
Anxiety Disorders ◽  
Feasibility Study ◽  
Self Management ◽  
Management Support ◽  
Support Tool ◽  
Mood And Anxiety Disorders
Sign in / Sign up

Export Citation Format

Share Document